Perspective
Our work in Perspective
-
How COVID Can Help Us Refocus on the How and Why of Value Assessment
The limitations of conventional approaches to value assessment are particularly clear when reflecting on our experience with the COVID-19 pandemic.
Categorized in -
Economic Incentives for Administrative Simplification
In the US health care system, payers, health systems, physicians, other clinicians, drug companies, pharmacies, and pharmacy benefit managers all earn more revenue because of administrative complexity.
Categorized in -
The Hidden Cost of Covid-19: Years of Life Lost Among the Young
The focus on deaths affecting mainly the elderly is unfortunate because it likely created a false sense of security among the young.
Categorized in -
Biosimilars Competition Helps Patients More Than Generic Competition
Well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
Categorized in -
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
Categorized in -
Money for the Infrastructure Bill is Coming at the Expense of Medicare Part D
The $1 trillion infrastructure bill will leave a lot of chronically ill people by the side of the road.
Categorized in -
Leveraging Rapid Antigen Tests in School-Aged Children
To keep schools safe, students enrolled at LAUSD schools were required to show a negative COVID-19 test in the two weeks prior to the first day. Is this a good use of scarce resources?
Categorized in -
After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More
Analyzing claims data, does COVID-19 related healthcare utilization persist in for 180 days or more, also known as long COVID, after their initial diagnosis?
Categorized in -
A Framework for Categorizing and Analyzing Prescription Drug Pricing Reform Options
Schaeffer Initiative experts present a framework for categorizing and analyzing a wide range of proposed policy reforms for prescription drug pricing.
Categorized in -
Government Regulated or Negotiated Drug Prices: Key Design Considerations
Americans pay much higher prices for brand drugs than do people who live in other industrialized nations. Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost. With 70 percent of Americans reporting that lowering drug costs is their highest healthcare priority, the Congress and the Biden Administration are considering how to lower US drug prices